EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

[ 18 F ] PSMA ‐1007 PET –Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer

Koji Hatano iD, Tadashi Watabe iD, Takero Hirata, Masatoshi Konishi, Tomohiro Kanaki, Masaru Tani, Toshiki Oka, Yu Ishizuya, Takuji Hayashi iD, Yoshiyuki Yamamoto iD, Taigo Kato, Atsunari Kawashima iD und 4 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Koji Hatano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The University of Osaka Graduate School of Medicine, Suita, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Recurrence, Local, Niacinamide, Bone Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) is a sensitive imaging modality for detecting recurrent prostate cancer following definitive local therapy. However, evidence on 18 F‐labeled PSMA tracers in Japanese patients with biochemical recurrence (BCR) remains limited. The aim of this study was to examine the recurrence site distribution by [ 18 F]PSMA‐1007 PET in patients with BCR and identify factors associated with metastatic disease.

Methods

We retrospectively analyzed 129 patients with prostate cancer who developed BCR after definitive local therapy and underwent [ 18 F]PSMA‐1007 PET. The primary endpoint was the distribution of recurrence sites detected by PSMA‐PET. Secondary endpoints included clinicopathological factors associated with metastatic disease. Exploratory endpoints involved outcomes of lesion‐directed therapy following PSMA‐PET.

Results

PSMA‐PET identified recurrent lesions in 83% ( n = 107), including local recurrence in 40% ( n = 51), lymph node metastasis in 43% ( n = 55), and bone metastasis in 26% ( n = 33); sites were not mutually exclusive. Metastatic lesions were detectable even at low prostate‐specific antigen (PSA) levels (≤ 1.0 ng/mL). In multivariate analysis, Grade Group ≥ 4 was independently associated with metastatic disease (odds ratio [OR], 2.65; 95% confidence interval [CI], 1.06–6.77), whereas a PSA doubling time ≥ 8.7 months was independently associated with a lower likelihood of metastasis (OR, 0.12; 95% CI, 0.05–0.27). Among 55 patients who underwent lesion‐directed therapy, PSA declines ≥ 90% were observed in 60% of cases.

Conclusions

In this Japanese cohort with BCR, [ 18 F]PSMA‐1007 PET delineated recurrence patterns and identified clinicopathological factors associated with metastatic disease. PSMA‐PET may provide clinically relevant information to support individualized salvage treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplasm Recurrence, LocalNiacinamideBone NeoplasmsPositron-Emission TomographyOligopeptidesHumansMaleRetrospective StudiesAgedLymphatic MetastasisMiddle AgedFluorine RadioisotopesRadiopharmaceuticalsProstate-Specific AntigenAged, 80 and overProstate

Stichwörter der Autor:innen

metastasispositron‐emission tomographyprostate cancerprostate‐specific antigenprostate‐specific membrane antigen

Substanzen

PSMA-1007NiacinamideOligopeptidesFluorine RadioisotopesRadiopharmaceuticalsProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Department of Radiology, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Institute for Radiation Sciences, The University of Osaka, Suita, Japan.
  • Department of Radiation Oncology, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Department of Urology, Kindai University Faculty of Medicine, Sakai, Japan.
  • Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan.

ORCID-Profile: Koji Hatano, Tadashi Watabe, Takuji Hayashi, Yoshiyuki Yamamoto, Atsunari Kawashima, Kazutoshi Fujita

Zitieren

APA

Hatano, K., Watabe, T., Hirata, T., Konishi, M., Kanaki, T., Tani, M., Oka, T., Ishizuya, Y., Hayashi, T., Yamamoto, Y., Kato, T., Kawashima, A., Fujita, K., Uemura, M., Giesel, F. L., & Nonomura, N. (2026). [ 18 F ] PSMA ‐1007 PET –Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer. International Journal of Urology. https://doi.org/10.1111/iju.70587

Vancouver

Hatano K, Watabe T, Hirata T, Konishi M, Kanaki T, Tani M, et al. [ 18 F ] PSMA ‐1007 PET –Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer. International Journal of Urology. 2026. doi:10.1111/iju.70587

BibTeX
@article{Hatano2026,
  author = {Hatano, Koji and Watabe, Tadashi and Hirata, Takero and Konishi, Masatoshi and Kanaki, Tomohiro and Tani, Masaru and Oka, Toshiki and Ishizuya, Yu and Hayashi, Takuji and Yamamoto, Yoshiyuki and Kato, Taigo and Kawashima, Atsunari and Fujita, Kazutoshi and Uemura, Motohide and Giesel, Frederik L and Nonomura, Norio},
  title = {[ 18 F ] PSMA ‐1007 PET –Based Recurrence Site Distribution and Predictors of Metastatic Disease in Patients With Biochemical Recurrence of Prostate Cancer},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70587}
}
Kostenlos starten →